AUA 2024 Bladder Cancer - Results from #40

Viewing 41-57 of 57 articles

AUA 2024: Predicting Response to Intravesical BCG in High Risk Non-Muscle Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12 Center Cohort

AUA 2024: Phase I Study of Intravesical Fc-Optimized Anti-CD40 Agonist Antibody 2141-V11 for Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

AUA 2024: Paradigm-Shifting Clinical Trials in Urology: SWOG S1011 - Subgroup Analysis of the Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for MIBC

AUA 2024: Combination Regimen of Intravesical Docetaxel, Gemcitabine, and Cisplatin in Patients with BCG-unresponsive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

AUA 2024: A Phase II Trial of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG-Naïve Non-Muscle Invasive Urothelial Carcinoma of the Bladder

AUA 2024: Comparison of BCG to Gemcitabine/Docetaxel in The Intermediate Risk Group Composed Mostly of TaHG

AUA 2024: Urinary Minimal Residual Disease Detection Predicts Recurrence in BCG-Unresponsive NMIBC and Quantifies Molecular Response to Nadofaragene Firadenovec

AUA 2024: TAR-200 in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results from the SunRISe-1 Study

AUA 2024: Beyond the Tumor: Exploring the Financial Toxicity of Non-Muscle Invasive Bladder Cancer in a Diverse, Urban Population

AUA 2024: Replacing ReTUR with Cystoscopy in High-Grade T1 NMIBC Patients: Confirmatory Results from the HuNIRe Trial

AUA 2024: N-803 plus BCG Complete Response Rate in NMIBC CIS: BCG Refractory, Relapsed, Checkpoint Failure, and Chemotherapy Failure; Updated Results (QUILT 3.032)

AUA 2024: A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients with Microhematuria: The STRATA: Safe Testing of Risk for Asymptomatic Microhematuria Trial

AUA 2024: Challenging the Paradigm of "BCG Unresponsive" Bladder Cancer: Does Additional BCG Have an Effect?

AUA 2024: Effects of Neoadjuvant Chemotherapy on Rates of Depression in Muscle Invasive Bladder Cancer

AUA 2024: The International Bladder Cancer Group Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts the Need for Intervention for Patients on Active Surveillance

AUA 2024: Smoking Status is Associated with Poor Mental Health in Bladder Cancer Patients and Survivors

AUA 2024: Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

1
2
3